Lifecare ASA

Regulatory Filings • Oct 14, 2024

Lifecare presentation at the Diabetes Technology Meeting 2024.

Lifecare presentation at the Diabetes Technology Meeting 2024.

Bergen, Norway, October 14, 2024: Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM) will present a poster at the Diabetes Technology Meeting (DTM)

in Burlingame, California, an international diabetes technology conference

hosted by the Diabetes Technology Society.

As the DTM returns as a face-to-face meeting after three years of virtual

set-up, Lifecare is pleased to be present at the conference to present a

poster presentation on October 16th with the title "Continuous Glucose

Monitoring with an Osmotic-Pressure Based Continuous Glucose Sensor -- Human

Pilot Study Results and Next Development Steps".

The results from Lifecare's clinical study LFC-SEN-001 has previously been

presented at the American Diabetes Association Scientific Sessions (ADA) in

San Diego, CA, USA, in June 2023, and with additional data at the virtual DTM

2023. At the upcoming event Lifecare will in addition present ongoing and

upcoming development steps in the longevity study LFC-SEN-002.

The clinical study data presented at the ADA 2023 and DTM 2023 included the

technology proof-of-concept in human tissue, as well as confirmation that

Lifecare's CGM system Sencell has a solid clinical accuracy. The initial data

from Lifecare's ongoing longevity study LFC-SEN-002 has confirmed a 12-week

operational sensor lifetime in live tissue, without any unexpected tissue

reactions.

From the clinical study data, Lifecare calculated a Mean Absolute Relative

Difference (MARD) value of 9,6%. In context, regulatory authorities expect a

MARD below 10% to acknowledge CGMs for therapeutic (medical) decisions, such

as insulin dose adjustments. In comparison, the MARD of glucose measurements

in capillary blood (Blood Glucose Monitoring -- BGM), representing the gold

standard for patient self-monitoring of glucose, are in the range 5-10%.

The Sencell MARD calculated in 2023 indicates accuracy comparable with

commercially available CGM systems.

On October 10th, 2024, Lifecare announce that the company's next human study

protocol has been internally concluded, with the aim to progress the clinical

sensor development towards regulatory approval.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42